CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis (MF) and systemic mastocytosis (SM).
  
  LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
  • Analyze how patient age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
  • Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize therapeutic decision-making.
  • Assess available research findings with novel investigational strategies, and consider the future clinical application of these approaches for patients with MF.
  • Use an understanding of disease biology to appropriately classify SM, and effectively counsel patients diagnosed with this disease regarding their long-term prognosis.
  • Recall the rationale for targeting the KIT D816V mutation in SM, and appreciate the current role of selective kinase inhibitors of D816V-mutated KIT for patients with indolent and advanced disease.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CE ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMF25/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASHMF25/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMF25/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASHMF25.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Professor Claire Harrison
  Professor of Myeloproliferative Neoplasms
  Guy’s and St Thomas’ NHS Foundation Trust
  London, United Kingdom
  
  Advisory Committees: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi; Consulting Agreements: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi, Takeda Pharmaceutical Company Limited; Contracted Research: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, Silence Therapeutics, Sobi; Data and Safety Monitoring Boards/Committees: Galecto Inc, Incyte Corporation, Novartis, Silence Therapeutics; Speakers Bureaus: AOP Health, GSK, Incyte Corporation, Novartis.
  
  Andrew T Kuykendall, MD
  Associate Member, Department of Malignant Hematology
  Moffitt Cancer Center
  Associate Professor, Department of Oncologic Sciences
  University of South Florida
  Tampa, Florida
  
  Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Boards/Committees: Geron Corporation.
  
  Stephen T Oh, MD, PhD
  Professor of Medicine
  Co-Chief, Division of Hematology
  Washington University School of Medicine
  St Louis, Missouri
  
  Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation, Morphic Therapeutic, a wholly owned subsidiary of Lilly, MorphoSys, Protagonist Therapeutics; Stock Options — Private Companies: Harmonic Discovery, Phoenix Molecular Designs.
  
  Jeanne Palmer, MD
  Associate Professor of Medicine
  Mayo Clinic in Arizona
  Phoenix, Arizona
  
  Presentation (Money to Institution — Not Speakers Bureau): CTI BioPharma, a Sobi Company.
  
  Raajit K Rampal, MD, PhD
  Associate Member, Director
  MPN and Rare Hematologic Malignancies Program
  Director, Center for Hematologic Malignancies
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Blueprint Medicines, Bristol Myers Squibb, GSK, and Incyte Corporation.
  
  Release date: January 2026
  Expiration date: January 2027
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.